| Purpose:Immunoreaction trigger the main injuries of allograft vasculopathy.Cellular immunity and humoral immunity cause the injuries of allograft vasculopathy in acute rejection.The mechanisn of this injuries is very complex.The effect of routine antirejection therapy is troublesome. This experiment is to explore the value of paclitaxel-liposome compound and its effect of therapy on allograft vasculopathy in acute rejection after liver transplantion in rats by using nano-biotechnology.Methods:The contents of this paper include two parts.The first part is the preparaty of paclitaxel-liposome compound and its pharmacokinetics and biologic security.The second part is to describe the proess and methods in rats liver tranplantion models.Sprague-Dawley rats were randomly divided into three groups(CsA group,paclitaxel group,paclitaxel-liposome compound group).Two week late,enzyme linked immunosorbent assay(ELISA)were performed for testing the levels of serum VEGF,TNF-a,IL-2 and the expressions of CDK2,Cyclin E protein.VSMC apoptosis in hepatic tissues was evaluated by using the technique of terminal deoxynucleotidyl transferasebiotin nick end-labeling(TUNEL). The purpose of this paper is to investigate inhibitory effect of the paclitaxel-liposome compound on vasculopathy damage in acute rejection after liver transplation in rats.Result:The result showed the mean diameter and drug envelopment rate of paclitaxel-liposome compound were 115.1nm,65.3%respectively.The paclitaxel-liposome compound targeted evidently to liver and was very biocompatible.The paclitaxel-liposome compound could significantly down-regulate the express of CDK2 and Cyclin E protein,and increase VSMC apoptosis,also inhibite the vasularization,also could reduce the produce of VEGF,TNF-a,IL-2.The inhibitory effect of the paclitaxel-liposome compound group on allograft vasculopathy significantlly surpassed that of paclitaxel group and CsA group.Conclution:The paclitaxel-liposome compound argeted evidently to liver and was very biocompatible.It could lighten the injuiris of allograft vasculopathy in acute rejection after liver transplation in rats.As a new aided immunity inhibitory preparation.The paclitaxel-liposome compound has its potention value for lessening the allograft vasculopathy injuiris in acute rejection after liver transplation. |
PDF Full Text Request